Deciphera presents results from ctDNA analysis of INTRIGUE Phase III in GIST

25 January 2023

Deciphera Pharmaceuticals’ (Nasdaq: DCPH) shares rose 4.4% to $18.85 in after-hours trading yesterday, when the US biopharma company presented additional data from the planned exploratory analysis from the INTRIGUE Phase III clinical study of Qinlock (ripretinib) using circulating tumor DNA (ctDNA) from patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib.

The presentation titled Mutational heterogeneity of imatinib resistance and efficacy of ripretinib versus sunitinib [Pfizer's Sutnt] in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE was made by Dr Sebastian Bauer, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium at the American Society of Clinical Oncology (ASCO) Plenary Series Session.

Qinlock was approved by the US Food and Drug Administration in May 2020, with marketing authorizations following elsewhere, including in Europe, Canada and the UK. Analysts at Stifel expect peak sales of just $200 million for the drug, which assumes that ex-USA use will ramp to match US revenues.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK